oral
nasal
administr
interferon
shown
number
studi
protect
effect
viral
infect
major
studi
suggest
oral
nasal
administ
interferon
exert
antivir
activ
local
cummin
hutcheson
cummin
rosenquist
greenberg
et
al
hayden
et
al
higgin
etal
merigan
etal
schaferet
smith
et
al
turner
et
al
recent
number
studi
suggest
oral
administ
interferon
might
exert
antivir
activ
system
effect
cummin
et
al
hutchinson
cummin
koech
et
al
studi
extend
origin
observ
antivir
activ
oral
administ
interferon
includ
demonstr
immunoregulatori
antiparasit
activ
oral
administ
interferon
cummin
hutcheson
fleischmann
et
al
young
et
al
addit
studi
extend
observ
oral
administr
interferon
includ
immunoregulatori
antibacteri
activ
mediat
oral
administr
cytokin
baqar
et
al
koren
fleischmann
concept
oral
administr
interferon
could
system
effect
difficult
one
evalu
difficult
understand
oral
administ
interferon
particularli
ph
sensit
could
surviv
passag
acid
andor
peptidas
rich
environ
stomach
intestin
tract
trigger
system
effect
one
concern
involv
lack
parallel
control
mani
studi
concern
involv
question
biolog
relev
often
rel
modest
effect
obtain
oral
administ
interferon
concern
relat
lack
univers
observ
biolog
effect
oral
administ
interferon
sperber
et
al
witt
et
al
efficaci
interferon
therapi
may
depend
upon
form
diseas
acut
persist
daili
dosag
interferon
type
interferon
prepar
whether
made
natur
recombin
sourc
furthermor
type
diseas
durat
therapi
may
influenc
final
respons
treatment
concern
real
appropri
attend
upon
research
investig
oral
administr
cytokin
address
effect
oral
administr
cytokin
topic
number
present
recent
workshop
present
conjunct
annual
meet
intern
societi
interferon
cytokin
research
budapest
hungari
mechan
oral
administ
ifna
might
exert
antivir
effect
probe
vitro
studi
cultur
primari
human
buccal
epitheli
cell
smith
etal
david
chi
colleagu
use
floresc
studi
show
ifna
treatment
significantli
increas
number
hladr
posit
cell
trend
toward
greater
express
hladr
hladr
posit
cell
also
observ
indic
ifna
caus
upregul
hladr
express
human
buccal
epitheli
cell
peripher
white
blood
cell
suggest
oral
administ
ifna
may
exert
antivir
activ
local
viral
infect
anfivir
activ
may
medic
least
part
greater
degre
recognit
viral
infect
cell
context
hladr
host
immun
system
mechan
oral
administ
ifna
might
exert
antimicrobi
action
examin
studi
report
kunihiro
ohashi
colleagu
found
saliva
healthi
volunt
contain
illa
establish
epitheli
cell
line
also
found
produc
illa
spontan
possibl
immunolog
role
ifna
combin
lymphokin
evalu
vitro
use
level
equival
saliva
ifnc
examin
cooper
effect
activ
neutrophil
mediat
anticandid
action
found
addit
effect
product
found
enhanc
treatment
establish
epitheli
cell
line
ifnc
treatment
ifna
also
found
partial
restor
product
monocyt
cell
line
latent
infect
human
immunodefici
final
ifna
treatment
detroit
pharyng
cancer
cell
line
kb
cell
oral
cancer
cell
line
caus
enhanc
bind
human
cell
line
suggest
ifna
caus
enhanc
recognit
tumor
cell
regard
investig
show
enhanc
express
oralmucos
epitheli
cell
treat
ifna
vitro
taken
togeth
work
provid
vitro
evid
support
concept
vivo
oral
administr
ifna
may
local
activ
neutrophil
buccal
caviti
exhibit
greater
antimicrobi
action
b
affect
local
lymphokin
product
epitheli
cell
contact
ifna
c
increas
cell
surfac
antigen
mucos
epitheli
cell
make
sensit
tumor
surveil
mechan
mari
tompkin
report
effect
intranas
administ
ifna
lymphoid
cell
phenotyp
function
lymph
node
spleen
tonkonogi
et
al
colleagu
show
lymphocyt
isol
periglandular
lymph
node
respond
vitro
stimul
immobil
activ
cell
produc
control
mice
lymphocyt
superfici
cervic
lymph
node
oral
ifnatr
mice
produc
control
mice
differ
product
detect
lymphocyt
distal
lymphoid
organ
axillari
lymph
node
mesenter
lymph
node
peyer
patch
spleen
ifna
control
mice
effect
oral
administ
ifna
express
cell
surfac
marker
lymphocyt
lymphoid
tissu
also
measur
differ
proport
express
cell
degre
express
cell
surfac
mhc
class
ii
immunoglobulin
seen
lymphocyt
lymphoid
tissu
ifna
treat
control
mice
result
indic
intranas
administr
ifna
establish
greater
respons
lymphocyt
periglandular
superfici
lymph
node
induct
exposur
greater
respons
occur
absenc
chang
phenotyp
lymphocyt
result
suggest
effect
intranas
administr
ifna
product
may
primarili
local
effect
sinc
diminish
increas
distanc
site
ifna
administr
paper
present
robert
fleischmann
summar
publish
work
myelosuppress
effect
oral
administ
interferon
mice
fleischmann
et
al
fleischmann
et
al
koren
fleischmann
present
review
work
show
oral
administr
three
interferon
ifna
exert
dose
depend
suppress
effect
peripher
white
blood
cell
count
fleischmann
et
al
moreov
peripher
white
blood
cell
suppress
shown
reflect
suppress
bone
marrow
function
oral
administ
interferon
koren
fleischmann
import
address
concern
biolog
relev
oral
administ
interferon
magnitud
peripher
white
blood
cell
bone
marrow
suppress
induc
oral
interferon
equival
induc
subcutan
intraperiton
administr
interferon
studi
kinet
establish
peripher
white
blood
cell
bone
marrow
suppress
indic
suppress
effect
develop
slowli
oral
administ
interferon
day
peripher
white
blood
cell
suppress
day
bone
marrow
suppress
inject
interferon
day
day
respect
final
mechan
establish
peripher
white
blood
cell
bone
marrow
suppress
oral
administ
interferon
inject
interferon
examin
fleischmann
et
al
contrast
observ
inject
interferon
system
activ
oral
administ
interferon
block
presenc
circul
antibodi
peripher
white
blood
cell
suppress
effect
oral
administ
interferon
shown
abl
adopt
transfer
inocul
white
blood
cell
otherwis
untreat
mice
studi
show
mous
model
oral
administ
interferon
potent
inject
interferon
suppress
peripher
white
blood
cell
count
bone
marrow
moreov
indic
mechan
oral
administ
interferon
exert
system
effect
differ
inject
interferon
studi
report
earlier
georgiad
et
al
georgiad
colleagu
found
antivir
state
could
transfer
oral
caviti
mice
treat
molfna
rat
peripher
blood
lymphocyt
spleen
cell
demonstr
white
blood
cell
mice
treat
iu
iu
ifn
could
transfer
antivir
resist
vitro
fetal
fibroblast
transfer
appar
happen
direct
cell
cell
contact
spleen
cell
mice
oral
treat
interferon
cocultur
fetal
fibroblast
absenc
interferon
previous
describ
blalock
baron
phenomenon
appear
within
hr
initi
oral
interferon
treatment
continu
oral
interferon
treatment
persist
least
day
neither
thymu
cell
plasma
oral
treat
mice
abil
transfer
antivir
effect
taken
togeth
control
experi
suggest
interferon
may
absorb
quickli
oral
caviti
cell
mucosa
somehow
activ
leukocyt
present
mucos
tissu
result
activ
leukocyt
lymphat
system
peripher
circul
paper
present
srecko
koren
report
parallel
observ
koren
fleischmann
oral
administr
shown
exert
system
effect
suppress
peripher
white
blood
cell
count
bone
marrow
dose
depend
manner
moreov
potenc
oral
administ
equival
inject
taken
togeth
result
fleischmann
observ
suggest
induct
system
effect
oral
administ
cytokin
may
gener
phenomenon
take
togeth
inform
appear
ifna
also
sever
interferon
cytokin
introduc
mucos
membran
oral
caviti
transfer
signal
mucou
membran
induc
system
respons
measur
varieti
techniqu
evid
system
effect
confirm
clinic
studi
carri
patient
chronic
activ
hepat
b
c
patient
aid
discuss
paper
present
shahida
baqar
report
effect
oral
administ
gut
mucos
immun
campylobact
jejuni
baqar
et
al
b
aqar
et
al
colleagu
show
oral
administr
result
log
reduct
rel
control
mice
amount
c
jejuni
excret
fece
within
hour
administr
c
jejuni
oral
administr
show
similar
reduct
though
time
cours
reduct
delay
rel
reduct
c
jejuni
observ
oral
administr
result
indic
oral
administr
reduc
initi
colon
c
jejuni
durat
effect
three
lymphokin
probe
rechalleng
mice
treat
oral
administr
establish
recolon
c
jejuni
result
indic
three
lymphokin
initi
level
recolon
log
lower
control
anim
howev
recolon
ultim
progress
level
control
treat
anim
treat
anim
show
durabl
suppress
c
jejuni
colon
specif
iga
antibodi
respons
c
jejuni
also
measur
mice
treat
oral
three
lymphokin
treat
mice
treat
mice
show
enhanc
level
c
jejunispecif
iga
antibodi
intestin
blood
experi
effect
oral
administ
lymphokin
iga
product
evalu
potenti
oral
mucos
adjuv
vaccin
formalinkil
c
jejuni
threefold
enhanc
siga
observ
rel
control
mice
enhanc
slga
activ
biolog
relev
sinc
led
enhanc
rate
clearanc
c
jejuni
intestin
reduc
number
c
jejuni
present
fece
oral
administr
ifna
previous
report
efficaci
treatment
felin
leukemia
cummin
et
al
thoma
toth
report
doubleblind
studi
evalu
effect
oral
administ
ifna
variou
hematolog
variabl
felin
leukemia
virusposit
cat
toth
et
al
hematolog
paramet
measur
includ
total
red
blood
cell
count
total
white
blood
cell
count
differenti
white
blood
cell
count
total
hemoglobin
mean
corpuscular
hemoglobin
mean
corpuscularhemoglobin
concentr
mean
corpuscular
volum
hematocrit
oral
treatment
given
time
day
dosag
level
unitstreat
hematolog
variabl
monitor
day
oral
administ
affect
one
hematolog
variabl
reduc
mean
corpuscular
hemoglobin
concentr
signific
level
day
cat
treat
unit
day
mean
corpuscular
hemoglobin
concentr
return
control
level
oral
treatment
ifna
given
time
day
dosag
level
iutreat
hematolog
variabl
monitor
day
oral
administr
ifna
caus
signific
dose
depend
elev
total
red
blood
cell
count
total
hemoglobin
hematocrit
day
interestingli
iutreat
monocyt
count
also
significantli
elev
day
hematolog
variabl
control
level
result
indic
oral
administr
ifna
affect
sever
hematolog
variabl
suggest
biolog
respons
modifi
caus
system
effect
biolog
import
system
effect
relev
control
felin
leukemia
viru
infect
yet
unknown
final
miklo
degr
report
studi
effect
oral
administr
two
biolog
respons
modifi
cours
enter
bacteri
infect
mice
degr
found
oral
administ
tumor
necrosi
factor
effect
cours
infect
howev
oral
administ
ifna
reduc
mortal
infect
mice
rel
control
degre
mortal
oral
administ
ifna
observ
intraperiton
administ
ifnc
result
suggest
oral
administr
ifna
may
exert
protect
effect
enter
bacteri
pathogen
race
hors
suffer
inflammatori
airway
diseas
impair
abil
perform
race
track
bonni
moor
present
result
doubleblind
placebo
control
studi
efficaci
oral
ifna
treatment
inflammatori
airway
diseas
hors
randomli
assign
horsesgroup
placebo
group
three
ifna
dosag
group
iuday
day
fifteen
day
initi
therapi
hors
evalu
degre
inflammatori
airway
diseas
semiquantit
endoscop
examin
score
cytolog
evalu
bronchoalveolar
lavag
fluid
oral
administr
iu
ifna
result
reduct
endoscop
examin
score
well
reduct
number
white
blood
cell
bronchoalveolar
lavag
fluid
administr
iu
ifna
efficaci
rel
percentag
variou
lymphocyt
subpopul
unaffect
ifna
treatment
result
suggest
oral
administ
ifna
may
benefici
effect
inflammatori
airway
diseas
hors
previous
publish
work
suggest
oral
administr
ifna
may
use
treatment
patient
aid
hutchinson
cummin
koech
et
al
two
present
discuss
work
evalu
efficaci
oral
administ
ifna
hiv
one
present
evalu
efficaci
oral
administ
ifna
felin
leukemia
viru
musabbir
mian
report
studi
poland
patient
aid
arc
aid
relat
complex
given
low
dose
oral
treatment
ifna
babiuch
mian
report
repres
result
studi
initi
four
year
earlier
part
studi
alreadi
publish
babiuch
et
al
georgiad
babiuch
found
confirm
other
jordan
report
patient
initi
cell
count
becam
asymptomat
gain
weight
improv
karnofski
perform
score
either
increas
stabl
cell
count
total
lymphocyt
count
patient
initi
cell
count
respond
oral
ifno
martin
cummin
report
doubleblind
placebo
control
studi
zambia
involv
patient
divid
randomli
equal
three
treatment
group
group
placebo
group
iuday
ifna
administ
altern
weekli
basi
placebo
week
group
iuday
ifna
administ
continu
week
mukunyandela
et
al
studi
show
oral
ifna
treatment
signific
effect
reduc
hivrel
sign
infect
group
significantli
greater
resolut
preexist
hivrel
skin
infect
placebo
treat
group
group
greatli
reduc
incid
new
mucocutan
hsv
infect
compar
placebo
treat
group
group
intermedi
valu
interestingli
patient
altern
ifnaplacebo
group
continu
ifna
group
show
reduct
global
symptom
score
small
signific
increas
absolut
mean
count
compar
placebo
treat
group
taken
togeth
studi
provid
signific
support
concept
oral
administ
ifna
may
benefici
effect
aid
patient
provid
treat
earli
stage
diseas
caution
howev
sever
neg
studi
report
show
lack
efficaci
oral
administ
ifna
treatment
hiv
infect
patient
hulton
et
al
sperber
et
al
neg
observ
may
relat
limit
period
oral
ifna
treatment
employ
studi
use
recombin
oppos
natur
ifna
possibl
certain
anti
hiv
effect
oral
ifna
human
sever
studi
provid
addit
support
observ
aid
patient
baselin
cell
count
cellsmm
respond
poorli
oral
ifna
therapi
agreement
report
kaiser
et
al
germani
hutton
et
al
canada
sperber
et
al
usa
studi
report
similar
find
patient
cellsmm
respond
well
ifna
therapi
howev
patient
baselin
cell
count
cellsmm
surviv
longer
control
patient
requir
much
less
medic
attent
patient
control
group
babiuch
mian
georgiad
babiuch
observ
confirm
report
california
physician
similar
experi
hivlinfect
patient
jordan
interestingli
benefici
effect
ifna
therapi
may
constant
cours
ifna
therapi
babiuch
report
time
time
patient
may
appar
lose
sensit
oral
ifna
therapi
babiuch
mian
georgiad
babiuch
appar
loss
sensit
ifna
therapi
deterior
clinic
statu
revers
slightli
increas
dose
ifnc
babiuch
mian
observ
may
repres
clinic
manifest
phenomenon
describ
vitro
yamamoto
colleagu
yamamoto
et
al
investig
examin
effect
ifna
use
longterm
cultur
white
blood
cell
observ
transient
loss
sensit
white
blood
cell
ifna
transient
loss
observ
twice
day
cultur
period
studi
need
determin
resist
observ
vivo
vitro
occur
mechan
small
scale
trial
hepat
b
patient
chronic
activ
hepat
previous
suggest
oral
administr
ifna
might
therapeut
benefit
similar
benefici
result
seen
small
scale
trial
six
hepat
c
patient
chronic
activ
hepat
treat
oral
ifna
zielinska
report
longterm
followup
hepat
b
patient
chronic
activ
hepat
treat
oral
ifna
zielinska
et
al
diagnosi
chronic
activ
hepat
base
clinic
biochem
sign
activ
diseas
oral
ifna
given
daili
dose
iuday
depend
bodi
weight
patient
averag
month
seroconvers
hbeag
antihb
observ
patient
median
time
seroconvers
week
addit
two
patient
seroconvert
hbsag
antihb
patient
seroconvert
antihb
hbv
dna
found
present
serum
also
biochem
marker
associ
liver
function
return
normal
rang
patient
seroconvert
antihb
neg
presenc
hbv
dna
serum
remain
patient
serum
hbv
dna
level
significantli
lower
initi
oral
ifna
treatment
taken
togeth
observ
suggest
oral
ifna
may
effect
therapi
control
chronic
activ
hepat
annual
meet
intern
societi
interferon
cytokin
research
held
budapest
provid
first
time
compel
evid
oral
dose
cytokin
modul
immun
function
increas
resist
infecti
diseas
studi
present
investig
number
differ
laboratori
clinic
data
especi
human
indic
ifn
given
though
oral
mucosa
capabl
induc
system
reaction
may
potenti
new
therapeut
method
number
differ
laboratori
report
studi
oral
administ
interferon
cytokin
observ
extend
previou
observ
show
oral
administ
interferon
cytokin
exert
local
system
effect
difficult
may
understand
oral
administ
interferon
cytokin
may
exert
effect
increas
number
laboratori
demonstr
biolog
effect
oral
administ
cytokin
suggest
seriou
consider
given
possibl
oral
administ
interferon
cytokin
inde
exert
effect
also
rais
possibl
effect
may
biolog
relev
treatment
human
diseas
moreov
may
indic
nasalor
region
window
environ
import
howev
assur
experi
perform
special
care
avoid
present
preliminari
data
properli
control
essenti
carri
studi
suffici
anim
patient
ascertain
signific
plan
studi
doubleblind
evalu
avoid
misinterpret
subject
test
use
nevertheless
overal
data
present
give
one
impress
area
pursu
